Reta / Carg Blend (Retatrutide / Cagrilintide)
Retatrutide + Cagrilintide · Reta-Carg
An aggressive weight blend pairing a triple incretin agonist with an amylin analogue.
Class
Retatrutide + Cagrilintide blend
Half-life
~6–8 days (both once-weekly)
Evidence
Limited human data
Limited human data
Small open-label studies, case series, or trials in a narrow population. Directionally informative, not conclusive.
Overview
This blend pairs retatrutide — the investigational GIP/GLP-1/glucagon triple agonist — with cagrilintide, the long-acting amylin analogue. The logic is stacking two non-overlapping satiety mechanisms (incretin plus amylin) for maximal appetite suppression and weight loss, mirroring the CagriSema strategy but with the more powerful triple agonist as the base.
It is the most aggressive weight-loss combination in the catalog, and also the least proven: retatrutide has only phase 2 data, cagrilintide is unapproved, and the specific combination has no dedicated trials. The side-effect and cardiovascular cautions of retatrutide (notably heart-rate elevation) apply in full, compounded by additive GI effects.
How it works
- Retatrutide agonises GLP-1, GIP, and glucagon receptors — reduced intake plus increased energy expenditure.
- Cagrilintide agonises amylin/calcitonin receptors — additional satiety via a separate pathway.
- The two satiety mechanisms are complementary, driving a larger caloric deficit.
What the research shows
Researched effects
- Very large appetite suppression and weight loss (extrapolated from component data)
- Improved glycemic and hepatic-fat markers (retatrutide)
- No dedicated human trials of this specific blend
Limitations & what it won't do
- No trials of the combination; retatrutide itself is only phase 2.
- Additive GI side effects can be significant.
- Retatrutide's heart-rate elevation and cardiovascular unknowns apply.
Dosing protocols
These ranges reflect published trials and community protocols. They are reference information, not a prescription. Doses are per injection unless noted.
Titrated protocol (reference only)
Low and titrated per componentFixed-ratio blends make independent titration impossible, which is a real drawback for two compounds that both need careful up-titration. Clinical supervision strongly advised.
Reconstitution & measuring your dose
Handling
- Typical vial sizes
- 10 mg
- Suggested BAC water
- 2 mL
- Storage
- Lyophilised powder refrigerated at 2–8 °C, protected from light.
- After reconstitution
- Reconstituted: approximately 28 days refrigerated.
Why 2 mL? A 5/5 mg blend vial (10 mg total) in 2 mL yields 5 mg/mL total. Because the ratio is fixed, every dose delivers both compounds together — you cannot titrate one without the other.
Dose calculator
Draw to
5units
= 0.05 mL · 50 mcg per unit
Concentration
5000 mcg/mL
Doses per vial
40
Side effects
Common
- Nausea and vomiting (often significant)
- Constipation/diarrhoea
- Increased resting heart rate (retatrutide)
- Fatigue
- Marked appetite loss
Serious / rare
- Pancreatitis (incretin class)
- Gallbladder disease with rapid weight loss
- Unknown long-term cardiovascular risk from glucagon agonism
- Hypoglycemia with diabetes medication
Contraindications & interactions
Do not use if you have
- Medullary thyroid carcinoma or MEN2 (personal or family)
Incretin-class thyroid C-cell contraindication (retatrutide). Absolute.
- Pregnant, breastfeeding, or trying to conceive
No pregnancy safety data.
- Pancreatitis history
Incretin-class pancreatitis signal.
- Cardiovascular disease
Retatrutide's sustained heart-rate elevation with no cardiovascular outcomes data makes established CVD unacceptable.
- Arrhythmia or palpitations
Heart-rate elevation is additive to a rhythm disorder.
Use caution if you have
- High blood pressure
Heart-rate elevation warrants monitoring.
- Gallbladder disease or gallstones
Rapid weight loss raises gallstone risk.
- Gastroparesis or delayed gastric emptying
Both components slow gastric emptying.
Medication interactions
- avoidInsulin — Serious hypoglycemia risk; requires prescriber-managed reduction.
- avoidSulfonylureas — Additive hypoglycemia risk.
- avoidGLP-1 / GIP agonists — Contains GLP-1 agonism — never add another.
- avoidStimulants — Additive heart-rate and blood-pressure elevation.
Don't stack with
- Semaglutide — Duplicate GLP-1 agonism.
- Tirzepatide — Duplicate incretin agonism.
What to monitor
- Resting heart rate and blood pressure weekly
- Glucose
- Gallbladder symptoms
- Body composition
Commonly combined with
References
- See component profilesRetatrutide (phase 2) and Cagrilintide
Research & educational information only — not medical advice.
You must be 18 or older to use this site. The peptides described are presented as research chemicals intended for research purposes only. Most are not approved by the FDA for human use. Dosing ranges reflect what has appeared in the scientific literature or community protocols and are not prescriptions. Nothing here replaces evaluation by a licensed physician who knows your full medical history.
Want to know if Reta / Carg Blend (Retatrutide / Cagrilintide) fits your goals and history?
The assessment cross-checks your medical history and medications against this and every other compound before it recommends anything.
Start the assessment